Oriza Holdings
元禾控股
elsewhere's corpus does not genuinely cover Oriza Holdings as a subject. The bundle contains only passing mentions: it appears as a co-investor in Shize Biotech's 2022 round alongside Qiming Venture Partners and Lilly Asia Ventures , and as a follow-on investor in Yixi Biotech's 2023 Pre-A+ round led by Huangpu Bio . These references come from partner institutions' funding announcements (FreeS Capital and Oasis Capital), not from elsewhere's own reporting or any dedicated profile. No entity card, strategy description, founding date, fund size, or team details are present.
AI-generated — may contain errors, please verify.
Coverage
BlueRun Ventures Portfolio Company Puyu Technology Closes Hundreds of Millions of RMB Financing to Accelerate Nanoimprint Lithography Equipment Commercialization | BlueRun Family
Opening a New Front for China's Semiconductor Breakthrough
Breaking Into Silicon Valley, David Wei Blazes a New Trail for Dollar Funds | Getting in the Game
"There's no way to stop the exchange of ideas between people."
Oasis Capital's Early Investment *Yixi Bio* Closes Nearly 100 Million RMB Pre-A+ Round | Oasis Vitality
Counselor on Vitality
Heading Into the Next Spring Amid Winter: 7 Early-Stage Companies Raise Nearly 600 Million RMB | FreeS Family Funding News · Vol 13
Looking forward to working alongside more outstanding founders.
Two Decades of RMB Funds: Between Life and Death
Are USD Funds in Trouble? Is It the RMB Funds' Turn to Make a Move?
